Chi Podcasts

Informações:

Sinopsis

The CHI Podcasts are produced by the Cambridge Healthtech Institute and offer in-depth interviews with research and business leaders from many facets of biotechnology.

Episodios

  • Molecular Med Tri-Con 2020 | Artificial Intelligence in Precision Medicine

    15/01/2020 Duración: 23min

    Prof. Matthew Lungren shares his stories on how he got to where he is now and where his artificial intelligent inspiration for medicine comes from. He also talks about many great collaborations at the Stanford Center in precision medicine and what he’s looking to see more in this field in the next 5 years. For more information, please visit https://www.TriConference.com/Precision-Medicine

  • Molecular Med TriCon 2019 | Gene Therapy for Rare Disorders

    17/12/2019 Duración: 14min

    Gene therapy presents a promising path ahead for patients of rare diseases. The United States Food and Drug Administration’s Director of the Center for Biologics Evaluation and Research, Dr. Peter Marks discusses his work advancing production and availability of gene therapies for rare disorders, and the unique challenges to producing efficacious therapeutics in this field. For more information, please visit https://www.TriConference.com/Gene-Therapy

  • Immunogenicity Summit 2019 | From Cell & Gene Therapy to Biostatistics

    06/08/2019 Duración: 07min

    Nancy Sajjadi, an independent bioassay quality consultant with over 30 years of experience in biopharmaceutical product development, discusses her history in the bioassay field and how her experience has fostered her passion for teaching biostatistics to non-statisticians with CHI. Topics include: challenges in developing bioassays for cell & gene therapies, regulatory considerations and standards for bioassays, fostering collaboration between statisticians and bench scientists, and more For more information, please visit https://www.ImmunogenicitySummit.com/Workshop

  • Next Generation Dx 2019 | Launch a Paradigm Shift through an Innovative Diagnostic Test

    05/06/2019 Duración: 11min

    Prof. Joshua Krieger from Harvard Business School shares his perspectives on some of the challenges and opportunities in commercialization of diagnostic tests and gives us a preview of his business case study on Genomic Health. For more information, please visit https://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics

  • the Liquid Biopsy Summit 2019 | Reimagining Liquid Biopsy Applications with Epigenomics

    26/03/2019 Duración: 11min

    Samuel Levy of Bluestar Genomics speaks to CHI on March 13, 2019. Dr. Levy will be speaking during The Liquid Biopsy Summit, June 17-19, in San Francisco, CA. Topics include cell-free diagnostics in precision medicine, transformation & growth in the liquid biopsy field, epigenomic assays for cancer detection, and opportunities ahead. For more information, please visit https://www.LiquidBiopsySummit.com/Programs

  • Molecular DX Europe 2019 | Using Point-of-Care Diagnostics to Advance a One Health Approach

    05/03/2019 Duración: 08min

    Dr. Konstantinos Mitsakakis explains the One Health approach, and how the pursuit benefits diverse avenues of diagnostic research. For more information, please visit https://www.MolecularDXEurope.com/Point-of-Care-Dx

  • Molecular Med Tri-Con 2019 | Putting the AI in Wait

    01/03/2019 Duración: 07min

    Dr. Richard Levenson discusses the role of AI in digital pathology – what works, and what needs to be done for AI to reach its full potential. For more information, please visit https://www.TriConference.com/Digital-Pathology

  • Molecular Med Tri-Con 2019 | Real Precision Medicine is Starting with the Patient

    18/02/2019 Duración: 10min

    Harry Glorikian interviews Niven R. Narain about his approach on how to add more precision to the process of drug development and diagnostic development while engage more reproducibility. Niven also discusses how to use the biomarkers not only as a readout but as a vehicle and an agent to design clinical trials much differently. For more information, please visit https://www.TriConference.com/Precision-Medicine

  • Molecular Med Tri-Con 2019 | Target the Tumor Mutational Burden and Pursue Harmonization

    15/02/2019 Duración: 11min

    Dr. Mark Stewart discusses the role of the tumor mutational burden (TMB) in cancer research and the need for harmonization throughout the process. For more information, please visit https://www.triconference.com/Companion-Diagnostics

  • PEGS Boston 2019 | Jennifer Chadwick’s Story of Building a Creative and Authentic Career in Science

    08/02/2019 Duración: 12min

    Dr. Jennifer Chadwick shares her journey from academia to industry, and the best advice that got her to where she is today.

  • Bio-IT World | Advancing Life Sciences Research: Accelerating innovation in the age of cloud

    18/01/2019 Duración: 09min

    For decades, high-performance computing (HPC) has played a crucial role in advancing healthcare. Enabled by techniques like next-generation sequencing (NGS), modern computer systems have helped us understand the biology of disease and helped facilitate the development of newer more effective drugs. While once deployed mainly in research, today HPC is edging ever closer to front-line clinical care supporting advanced diagnostics, genetic counseling, and personalized medicine. While core bioinformatics applications aren’t going anywhere, modern medicine is increasingly a big data problem as well. Determining the optimal treatment depends on collaboration, the fusion of genetic data with other rich datasets like MRIs, ultrasound images, and population level studies. Increasingly analytics and AI techniques like machine learning are helping healthcare providers sift through massive amounts of data to make better decisions for patients more quickly and efficiently. For IT organizations, providing a foundation t

  • Molecular Med Tri-Con 2019 | Personalized Estimation of Motality Risk

    01/11/2018 Duración: 09min

    Dr. Bradley Perkins develops a digital platform that can estimate personalized ten year mortality risk. In this podcast, he shares with us what this platform is and how it works to protect and improve the health of individuals and families. In the era of personalized medicine, Dr. Perkins explains what the necessary steps to bring this platform to the general public, gives us other personalized medicine examples and how it will affect the cost of medical care. For more information, please visit http://www.TriConference.com/Precision-Medicine

  • Information Technology in Support of Genetics in the Clinic

    21/08/2018 Duración: 07min

    A re-upload of a podcast with Sandy Aronson, Executive Director, IT, Partners HealthCare Center for Personalized Genetic Medicine

  • Leveraging Health Information Exchange to Achieve Population Health Surveillance

    21/08/2018 Duración: 09min

    A re-upload of a podcast with Brian Dixon, MPA, Ph.D., FHIMSS, Assistant Professor, Health Informatics, Indiana University; Research Scientist, Regenstrief Institute; Investigator in Residence, Department of Veterans Affairs

  • Population Segmentation and Care Management in R&D of New Therapeutics

    21/08/2018 Duración: 13min

    A re-upload of a podcast with Marc Berger, M.D., Vice President, Real World Data & Analytics, Pfizer

  • Discovery on Target 2018 | Reprogramming Tumor Microenvironment to Enhance Immunotherapy

    16/08/2018 Duración: 10min

    Prof. Dai Fukumura gives a preview of his talk, shares some challenges of reprograming tumor microenvironment and what he would like to see more in this field. For more information, please visit http://www.DiscoveryOnTarget.com/Tumor-Myeloid-Cells/

  • Discovery on Target 2018 | Novel Strategies to Produce Better NK Cells for Cancer Treatment

    16/08/2018 Duración: 09min

    Dr. Jeffrey Miller shares his experience in NK cell field in the last 20 years, comparing NK cells with T cells and their cost differences along with giving some advice to the young scientists in the field. For more information, please visit http://www.DiscoveryOnTarget.com/NK-Cell-Based-Cancer-Immunotherapy/

  • Discovery on Target 2018 | Engineering NK Cells for Enhanced Potency and Persistence

    16/08/2018 Duración: 08min

    Dr. James Trager shares a preview of his talk at the NK cell-based cancer immunotherapy meeting in Boston, discusses his next step in research and the vision of Nkarta in NK cell therapy development and what he’s looking forward to at this meeting such as the topics of inhibition of MIC protein shedding and NK cell metabolism. For more information, please visit http://www.DiscoveryOnTarget.com/NK-Cell-Based-Cancer-Immunotherapy/

  • PEGS Europe 2018 | Transient Protein Gene Expression and Biotherapeutics

    23/07/2018 Duración: 08min

    Dr. Florian M. Wurm, Swiss Federal Institute of Technology Lausanne (EPFL) and ExcellGene SA speaks to Cambridge Healthtech Institute on 9 July 2018. He will be the keynote presenter during the Optimising Expression Platforms conference at PEGS Europe, 12-16 November 2018 in Lisbon, Portugal. For more information, please visit http://www.PEGSummitEurope.com/Optimising-Protein-Expression Topics Questions Include: Let's talk about transient protein expression. What advances do you foresee in this approach for enabling efficient engineering and expression of therapeutic proteins in the next decade? What potential solutions seem promising for some … challenges? Are there promising glimpses into using transient protein gene expression for clinical use today? You'll be discussing “Transient Protein (Gene) Expression: From R&D towards Pharmaceutical Manufacturing” during your keynote presentation on 14 November. What's the main theme you'd like to convey to your audience of protein engineers and researchers?

  • Bispecific Antibody Pipeline Congress 2018 | Checkpoint-binding Bispecific Antibodies

    17/07/2018 Duración: 04min

    Dr. John Haurum shares his perspective on the future of bispecific antibodies in the next 5 years, common myths about immune system activation using bispecifics and some novel compounds inside and outside of IO fields that he’s looking forward to the most at the Bispecific Antibody Pipeline Congress. For more information, please visit http://www.BispecificAntibodyCongress.com/Bispecific-Antibody-Clinical-Relevance

página 1 de 13